PUBLICATIONS DISCUSSED BY PAUL G RICHARDSON, MD

Abstracts listed in order of their review in the audio program

Abstract 76. San Miguel JF et al. MMY-3002: A Phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Proc ASH 2007.

Abstract 450. Harousseau JL et al. VELCADE/Dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantion (ASCT) in newly diagnosed multiple myeloma (MM): Updated results of the IFM 2005/01 trial. Proc ASH 2007.

Abstract 73. Cavo M et al. Bortezomib (Velcade^®)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Proc ASH 2007.

Abstract 74. Rajkumar SV et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Proc ASH 2007.

Abstract 187. Richardson P et al. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): Preliminary results of a Phase 1/2 study. Proc ASH 2007.

Abstract 817. Fenaux P et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 Phase III study. Proc ASH 2007.